Our articles provide quick read summaries to help keep you informed and looking forward with industry insights.
Globally, over 70,000 people are living with the often-debilitating effects of CF. While CFTR modulator treatments offer benefits for many, those with nonsense mutations require new therapies. ...
ETDRS BCVA is the primary endpoint for many, if not most, ophthalmic clinical trials. Learn about novel endpoints for visual function testing in this article. ...
Effective treatments for GBM remain a large unmet need in oncology. Developing an effective treatment is difficult due to many factors, including localization of tumors in the brain, resistance to therapy, migration of malignant cells into nearby brain tissue, and the blood-brain barrier. ...
CAR T-cell therapy for blood cancers may provide long-term remission for some patients, but their clinical benefit is limited by the complexity and cost of manufacturing and lack of efficacy in solid tumors. New developments in the field, however, offer hope to patients of greater...
Since the FDA approved ipilimumab, the first monoclonal antibody (MAB) blocking the immune checkpoint CTLA4, in 2011, immune checkpoint inhibitors have become some of the most widely prescribed anticancer treatments....
The FDA recently authorized Tezspire as the first asthma treatment targeting thymic stromal lymphopoietin (TSPL), a molecule involved in airway inflammation. While only 5% to 10% of asthma patients meet the criteria for severe asthma, more than 80% of total asthma healthcare costs can be...
AMD is a common eye condition and a leading cause of vision loss among people aged 50 and older. nAMD accounts for almost 90% of blindness associated with AMD....
Choosing an ophthalmology clinical trial endpoint services partner can be a labor-intensive and lengthy process. Do you ever wonder if you’re asking the right questions in your selection process?...
In today’s rapidly consolidating contract research organization (CRO) market, it’s important to be sure you’re partnering with the right company to provide you with the expert clinical trial endpoint services you need to advance your drug program....
MERIT’s CEO, Yijun Huang, PhD., shares his perspective about how big data impacts the pharma industry and the field of ophthalmology clinical trial research specifically. Read our article to discover three ways AI can assist in the field of image analysis for clinical trials....
Chronic lung disease, such as COPD, has higher rates in underserved communities such as minority and rural areas. Yet less than 5% of industry-sponsored respiratory-related clinical trials have reported racial or ethnic backgrounds....
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text]Clinical endpoint service providers offer a specific set of research services that revolve around a particular stage of clinical development or therapeutic area(s). Most providers increase value by helping you gain efficiencies and by providing deep scientific expertise...